MAP2K7 and breast carcinoma: HER2-positive breast cancer cells in which HER2-inhibitors such as lapatinib inhibit MEK/MAP signalling and activate PI3K/AKT signalling may be more likely to be sensitive to the anti-proliferative effects of refametinib.